Decoy Therapeutics (DCOY) CEO Frederick Pierce II Receives Award

What Happened Frederick Pierce II, CEO of Decoy Therapeutics (DCOY), was granted 33,455 restricted shares on August 31, 2026. The award was issued at a $0.00 price (i.e., a restricted stock grant rather than a purchase or option exercise). This is a compensation/retention award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-31 (filed with the SEC on 2026-09-02). Filing appears timely; no late filing indicated in the record provided.
• Transaction type: Grant/Award (Form 4 code A).
• Shares granted: 33,455 restricted shares at $0.00.
• Vesting: 25% vested immediately; remaining shares vest in approximately equal monthly increments over the next 36 months (footnote F1).
• Shares beneficially owned after the transaction: adjusted to reflect the reverse stock split effective March 6, 2026 (footnote F2); the filing notes the adjustment but a post-transaction total was not provided here.
• Not a sale or purchase in the open market—this is a compensation award.

Context Restricted stock awards are typically used for executive compensation and retention; they do not necessarily indicate immediate buying or selling sentiment by the insider. The immediate 25% vesting provides some near-term ownership transfer, while the remaining staggered vesting ties the CEO’s future gains to the company’s performance and continued service. The filing reflects the company’s post-split share counts per the March 6, 2026 reverse split.